# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-057312
Filing Date
2024-05-10
Accepted
2024-05-09 18:00:56
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nktr-20240331.htm iXBRL | 10-Q | 1486958
2 | EX-10.1(6) | nktr-ex10_16.htm | EX-10.1(6) | 45747
3 | EX-31.1 | nktr-ex31_1.htm | EX-31.1 | 13067
4 | EX-31.2 | nktr-ex31_2.htm | EX-31.2 | 13277
5 | EX-32.1 | nktr-ex32_1.htm | EX-32.1 | 9251
| Complete submission text file | 0000950170-24-057312.txt |  | 6310696

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nktr-20240331.xsd | EX-101.SCH | 1043125
62 | EXTRACTED XBRL INSTANCE DOCUMENT | nktr-20240331_htm.xml | XML | 925793

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 24932234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)